Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JACK H FLORIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1912990656
CMS profile
86422
Location
FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$120,576.43

289 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JACK H FLORIN

NPI 1912990656 · CMS profile ID 86422

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FULLERTON, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912990656?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JACK H FLORIN, NPI 1912990656, CMS profile ID 86422. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912990656?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JACK H FLORIN, NPI 1912990656, CMS profile ID 86422. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912990656?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JACK H FLORIN, NPI 1912990656, CMS profile ID 86422, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 6; records 101–150 of 289 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912990656?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

289 matching records · $120,576.43 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 289 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 289.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biogen, Inc. $2,688.0009/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838097 CMS
Biogen, Inc. $40.9509/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838099 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $22.5409/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 844026379 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $23.9809/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814972359 CMS
Biogen, Inc. $19.4909/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838107 CMS
Genentech, Inc. $16.7609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835920133 CMS
Lilly USA, LLC $525.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818553539 CMS
Lilly USA, LLC $1,400.0009/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818555179 CMS
CSL Behring $12.7209/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161551 CMS
EMD Serono, Inc. $4.7309/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849212039 CMS
EMD Serono, Inc. $20.9609/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849212047 CMS
Lilly USA, LLC $24.0709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819092285 CMS
EMD Serono, Inc. $1,200.0009/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849148533 CMS
UPSHER-SMITH LABORATORIES LLC $25.0309/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834687751 CMS
Teva Pharmaceuticals USA, Inc. $22.4608/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547377 CMS
Allergan, Inc. $1,920.0008/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792771647 CMS
Alexion Pharmaceuticals, Inc. $23.8008/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124247 CMS
Biogen, Inc. $1,152.0008/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838141 CMS
Biogen, Inc. $23.2108/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838105 CMS
Biohaven Pharmaceuticals, Inc. $21.0408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491449 CMS
Lundbeck LLC $1,062.5008/23/2021 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845907581 CMS
AbbVie Inc. $20.4808/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794486443 CMS
AbbVie Inc. $0.5808/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794486447 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $10.0308/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 814972453 CMS
Alexion Pharmaceuticals, Inc. $23.0208/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783124241 CMS
GENZYME CORPORATION $23.3008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843395773 CMS
Amgen Inc. $31.2508/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825369465 CMS
Biogen, Inc. $20.0208/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838129 CMS
AbbVie Inc. $7.6808/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794486439 CMS
Biohaven Pharmaceuticals, Inc. $7.0608/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491447 CMS
ACADIA Pharmaceuticals Inc $24.8108/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837998041 CMS
Supernus Pharmaceuticals, Inc. $13.5208/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845036861 CMS
BANNER LIFE SCIENCES, LLC $17.6808/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843739625 CMS
MDD US Operations, LLC $16.2307/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853055881 CMS
GENZYME CORPORATION $1,911.0007/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843395783 CMS
CSL Behring $22.9307/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820161545 CMS
AbbVie Inc. $17.1607/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794486435 CMS
Biohaven Pharmaceuticals, Inc. $3.2307/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491445 CMS
Janssen Pharmaceuticals, Inc $31.6607/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788820915 CMS
Biogen, Inc. $90.3907/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838139 CMS
Biohaven Pharmaceuticals, Inc. $22.7507/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491443 CMS
Celgene Corporation $16.8307/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783730569 CMS
Teva Pharmaceuticals USA, Inc. $2,080.0007/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839547317 CMS
Amgen Inc. $6.7007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825369461 CMS
Biogen, Inc. $384.0007/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827838091 CMS
Biohaven Pharmaceuticals, Inc. $2,550.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491439 CMS
Biohaven Pharmaceuticals, Inc. $120.5007/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852491441 CMS
Lilly USA, LLC $23.1407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819125649 CMS
EMD Serono, Inc. $25.5307/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849202373 CMS
Acorda Therapeutics, Inc $22.6407/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792553187 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $260,262.09 481
PY2020 $134,904.21 284
PY2021 $120,576.43 289
PY2022 $74,324.64 312
PY2023 $44,368.30 283
PY2024 $561.59 20
PY2025 $819.51 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $78,516.89 41
PY2025 Principal investigator $3,125,093.28 48
PY2024 Recipient $186,249.20 125
PY2024 Principal investigator $2,155,391.83 33
PY2023 Recipient $17,261.00 1
PY2023 Principal investigator $1,533,140.34 24
PY2022 Recipient $44,218.01 6
PY2022 Principal investigator $1,985,241.86 41
PY2021 Recipient $5,155.00 8
PY2021 Principal investigator $1,374,529.29 50
PY2020 Recipient $1,550.00 2
PY2020 Principal investigator $1,217,831.82 44
PY2019 Recipient $8,381.22 5
PY2019 Principal investigator $977,971.40 89

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Ipsen Innovation $881.76 12/24/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291294
Recipient Ipsen Innovation $2,254.56 12/24/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291296
Recipient Ipsen Innovation $881.76 12/24/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291298
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,990.00 12/16/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190309324
Recipient Novartis Pharmaceuticals Corporation $5,500.00 12/09/2025 Covered Recipient Physician A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190292265
Recipient Ipsen Innovation $85.80 11/24/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291292
Recipient Hoffmann-La Roche Limited $1,239.00 11/12/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536200
Recipient Hoffmann-La Roche Limited $5,819.85 11/12/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536206
Recipient Hoffmann-La Roche Limited $1,277.00 11/12/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536209
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,288.00 11/01/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190313971
Recipient Ipsen Innovation $881.76 10/27/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291286
Recipient Ipsen Innovation $1,754.28 10/27/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291288
Recipient Ipsen Innovation $1,148.40 10/27/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291290
Principal investigator 1 Ipsen Innovation $90.00 10/23/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287530
Principal investigator 1 Ipsen Innovation $270.00 10/23/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287532
Principal investigator 1 Ipsen Innovation $470.00 09/19/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287528
Principal investigator 1 Ipsen Innovation $300.00 09/03/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287526
Recipient Ipsen Innovation $1,148.40 08/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291278
Recipient Ipsen Innovation $2,902.68 08/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291280
Recipient Ipsen Innovation $2,376.00 08/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291282
Recipient Ipsen Innovation $881.76 08/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291284
Principal investigator 1 Genentech, Inc. $9,577.00 08/26/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617823
Principal investigator 1 Genentech, Inc. $9,577.00 08/26/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617826
Recipient Hoffmann-La Roche Limited $9,112.00 08/12/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536196
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,492.96 07/28/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235997267
Recipient Ipsen Innovation $2,376.00 07/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291272
Recipient Ipsen Innovation $2,902.68 07/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291274
Recipient Ipsen Innovation $881.76 07/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291276
Principal investigator 1 Ipsen Innovation $150.00 07/17/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287522
Principal investigator 1 Ipsen Innovation $450.00 07/17/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287524
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,546.64 07/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimers Disease (MINDSET 2) No dispute reported 06/30/2026 1235997265
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,805.00 07/01/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190304369
Recipient Ipsen Innovation $1,898.16 06/30/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291258
Recipient Ipsen Innovation $881.76 06/30/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291260
Recipient Ipsen Innovation $85.80 06/30/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291262
Recipient Ipsen Innovation $85.80 06/30/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291264
Recipient Ipsen Innovation $1,898.16 06/30/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291270
Principal investigator 1 Genentech, Inc. $9,577.00 06/18/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617771
Principal investigator 1 Ipsen Innovation $180.00 06/18/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287516
Principal investigator 1 Ipsen Innovation $300.00 06/18/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287518
Principal investigator 1 Ipsen Innovation $300.00 06/18/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287520
Recipient Hoffmann-La Roche Limited $1,347.00 06/17/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536192
Recipient Ipsen Innovation $1,500.00 06/11/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291266
Recipient Ipsen Innovation $150.00 06/11/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291268
Recipient Ipsen Innovation $225.00 05/09/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291254
Recipient Ipsen Innovation $1,500.00 05/09/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291256
Recipient Ipsen Innovation $1,898.16 04/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291236
Recipient Ipsen Innovation $881.76 04/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291238
Recipient Ipsen Innovation $881.76 04/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291240
Recipient Ipsen Innovation $1,898.16 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291242
Recipient Ipsen Innovation $881.76 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291244
Recipient Ipsen Innovation $881.76 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291246
Recipient Ipsen Innovation $1,891.56 04/28/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291248
Recipient Ipsen Innovation $881.76 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291250
Recipient Ipsen Innovation $2,254.56 04/28/2025 Covered Recipient Physician Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291252
Principal investigator 1 Ipsen Innovation $300.00 04/17/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287504
Principal investigator 1 Ipsen Innovation $180.00 04/17/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287506
Principal investigator 1 Ipsen Innovation $150.00 04/17/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287508
Principal investigator 1 Ipsen Innovation $90.00 04/16/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287510
Principal investigator 1 Ipsen Innovation $150.00 04/16/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287512
Principal investigator 1 Genentech, Inc. $9,009.00 04/15/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617791
Principal investigator 1 Genentech, Inc. $232.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617775
Principal investigator 1 Genentech, Inc. $9,577.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617779
Principal investigator 1 Genentech, Inc. $9,577.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617783
Principal investigator 1 Genentech, Inc. $232.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617787
Principal investigator 1 Genentech, Inc. $232.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617799
Principal investigator 1 Genentech, Inc. $9,577.00 04/14/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617802
Principal investigator 1 Ipsen Innovation $300.00 04/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287502
Principal investigator 1 Genentech, Inc. $232.00 04/11/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617807
Principal investigator 1 Ipsen Innovation $481.54 04/09/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287514
Principal investigator 1 Genentech, Inc. $303.00 04/08/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617795
Principal investigator 1 Genentech, Inc. $101.00 04/08/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617812
Principal investigator 1 Genentech, Inc. $303.00 04/08/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617816
Principal investigator 1 Genentech, Inc. $101.00 04/08/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC FULLERTON NEUROLOGY & HEADACHE
A PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB IN ADULTS WITH PROGRESSIVE MS No dispute reported 06/30/2026 1211617819
Principal investigator 1 Novartis Pharmaceuticals Corporation $241,302.23 03/31/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190304513
Recipient Hoffmann-La Roche Limited $10,525.00 03/25/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1211536188
Principal investigator 1 Sage Therapeutics, LLC $8,775.83 03/13/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580981
Recipient Ipsen Innovation $881.76 01/31/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291232
Recipient Ipsen Innovation $881.76 01/27/2025 Covered Recipient Physician A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184291234
Principal investigator 1 Sage Therapeutics, LLC $16,584.04 01/23/2025 Non-covered Recipient Entity
JACK H FLORIN MD INC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580536
Principal investigator 1 Ipsen Innovation $450.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287490
Principal investigator 1 Ipsen Innovation $90.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287492
Principal investigator 1 Ipsen Innovation $150.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184287494
Principal investigator 1 Ipsen Innovation $90.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287496
Principal investigator 1 Ipsen Innovation $450.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287498
Principal investigator 1 Ipsen Innovation $150.00 01/14/2025 Non-covered Recipient Entity
Fullerton Neurology And Headache Center
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1184287500
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,253,087.84 01/01/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190304367
Principal investigator 1 Novartis Pharmaceuticals Corporation $144.00 01/01/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190304509
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,491,328.20 01/01/2025 Non-covered Recipient Entity
FULLERTON NEUROLOGY AND HEADACHE CENTER
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190304511